145 related articles for article (PubMed ID: 37027330)
41. T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation.
Dorfman DM; Morgan EA; Pelton A; Unitt C
Hum Pathol; 2017 Jul; 65():166-174. PubMed ID: 28551327
[TBL] [Abstract][Full Text] [Related]
42. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
43. Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia.
Meng T; Qi J; Zhu Y; Xu Y; Chen F; Xue S; Miao M; Chen S; Han Y; Tang X; Qiu H; Sun A; Wu D; Wang Y
Hematol Oncol; 2021 Aug; 39(3):358-363. PubMed ID: 33521954
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia.
Coskun E; Neumann M; Schlee C; Liebertz F; Heesch S; Goekbuget N; Hoelzer D; Baldus CD
Leuk Res; 2013 Jun; 37(6):647-56. PubMed ID: 23522449
[TBL] [Abstract][Full Text] [Related]
45. CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.
Maciel ALT; Wolch K; Emerenciano M; Mansur MB
Genes Chromosomes Cancer; 2022 Jul; 61(7):437-442. PubMed ID: 35253299
[TBL] [Abstract][Full Text] [Related]
46. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.
Brammer JE; Saliba RM; Jorgensen JL; Ledesma C; Gaballa S; Poon M; Maziarz RT; Champlin RE; Hosing C; Kebriaei P
Bone Marrow Transplant; 2017 Jan; 52(1):20-27. PubMed ID: 27618682
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Summers RJ; Jain J; Vasileiadi E; Smith B; Chimenti ML; Yeung TY; Kelvin J; Wang X; Frye SV; Earp HS; Tyner JW; Dreaden EC; DeRyckere D; Graham DK
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551626
[TBL] [Abstract][Full Text] [Related]
48. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.
Danis E; Yamauchi T; Echanique K; Zhang X; Haladyna JN; Riedel SS; Zhu N; Xie H; Orkin SH; Armstrong SA; Bernt KM; Neff T
Cell Rep; 2016 Mar; 14(8):1953-65. PubMed ID: 26904942
[TBL] [Abstract][Full Text] [Related]
49. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
50. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
51. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
52. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
Aladag E; Aktimur SH; Aydın Ö; Demiroglu H; Buyukasik Y; Aksu S; Ozcebe OI; Haznedaroglu IC; Sayinalp N; Turgut M; Goker H
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):147-153. PubMed ID: 33451957
[TBL] [Abstract][Full Text] [Related]
54. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
Coustan-Smith E; Mullighan CG; Onciu M; Behm FG; Raimondi SC; Pei D; Cheng C; Su X; Rubnitz JE; Basso G; Biondi A; Pui CH; Downing JR; Campana D
Lancet Oncol; 2009 Feb; 10(2):147-56. PubMed ID: 19147408
[TBL] [Abstract][Full Text] [Related]
55. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
56. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
Bond J; Marchand T; Touzart A; Cieslak A; Trinquand A; Sutton L; Radford-Weiss I; Lhermitte L; Spicuglia S; Dombret H; Macintyre E; Ifrah N; Hamel JF; Asnafi V
Haematologica; 2016 Jun; 101(6):732-40. PubMed ID: 26944475
[TBL] [Abstract][Full Text] [Related]
57. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
[TBL] [Abstract][Full Text] [Related]
58. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
59. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
60. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
